Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Dec 22, 2024 7:23pm
96 Views
Post# 36374426

RE:ONCY Presented Positive GOBLET Pancreatic Cancer Data @ ESMO

RE:ONCY Presented Positive GOBLET Pancreatic Cancer Data @ ESMODecember 11, 2024 - Dr. Nadine van Montfoort and colleagues at Leiden University Medical Center have made significant strides in understanding the potential of 'Reo' (Reovirus type 3 Dearing/pelareorep) in cancer treatment.

In a recent study, coordinated by Dr. Christianne Groeneveldt, van Montfoort’s team confirmed that 
the immune-stimulating properties of 'Reo' can be harnessed to work by infecting and killing cancer cells directly and by stimulating the body’s immune system to attack the tumor, regardless of the presence of neutralizing antibodies.

They found that 
Reo is especially promising because it can prime a tumor microenvironment to become more amenable to immunotherapy. 
<< Previous
Bullboard Posts
Next >>